Equities analysts predict that Glaukos Corp (NYSE:GKOS) will report $59.96 million in sales for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Glaukos’ earnings. The highest sales estimate is $60.50 million and the lowest is $59.48 million. Glaukos posted sales of $54.08 million during the same quarter last year, which suggests a positive year-over-year growth rate of 10.9%. The business is expected to announce its next quarterly earnings report on Wednesday, February 26th.
On average, analysts expect that Glaukos will report full year sales of $231.11 million for the current fiscal year, with estimates ranging from $230.62 million to $231.70 million. For the next year, analysts expect that the company will post sales of $268.60 million, with estimates ranging from $267.30 million to $269.90 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that cover Glaukos.
Glaukos (NYSE:GKOS) last issued its earnings results on Wednesday, November 6th. The medical instruments supplier reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.07. Glaukos had a negative net margin of 8.60% and a negative return on equity of 4.01%. The company had revenue of $58.51 million during the quarter, compared to the consensus estimate of $56.96 million. During the same quarter in the prior year, the firm posted ($0.17) EPS. Glaukos’s quarterly revenue was up 33.2% compared to the same quarter last year.
In other Glaukos news, CFO Joseph E. Gilliam sold 2,500 shares of the business’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $73.25, for a total value of $183,125.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last quarter, insiders sold 10,881 shares of company stock worth $716,702. 8.70% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Glaukos by 9.7% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,274 shares of the medical instruments supplier’s stock valued at $171,000 after acquiring an additional 201 shares during the last quarter. Lisanti Capital Growth LLC increased its position in Glaukos by 1.1% in the second quarter. Lisanti Capital Growth LLC now owns 31,770 shares of the medical instruments supplier’s stock worth $2,395,000 after purchasing an additional 340 shares during the last quarter. JPMorgan Chase & Co. increased its position in Glaukos by 0.9% in the second quarter. JPMorgan Chase & Co. now owns 46,720 shares of the medical instruments supplier’s stock worth $3,544,000 after purchasing an additional 406 shares during the last quarter. NEXT Financial Group Inc raised its stake in Glaukos by 73.7% during the second quarter. NEXT Financial Group Inc now owns 1,129 shares of the medical instruments supplier’s stock valued at $85,000 after purchasing an additional 479 shares in the last quarter. Finally, Harvest Fund Management Co. Ltd purchased a new stake in Glaukos during the second quarter valued at $39,000.
NYSE:GKOS opened at $59.68 on Friday. The business’s 50-day simple moving average is $63.33 and its two-hundred day simple moving average is $67.80. Glaukos has a 52 week low of $50.60 and a 52 week high of $84.65. The stock has a market cap of $2.17 billion, a PE ratio of -161.30 and a beta of 1.66. The company has a quick ratio of 5.94, a current ratio of 6.32 and a debt-to-equity ratio of 0.42.
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma; and iStent inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry for the reduction of intraocular pressure in mild-to-moderate open-angle glaucoma in combination with cataract surgery.
See Also: Municipal Bonds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.